Signature Estate & Investment Advisors’s AstraZeneca AZN Stock Holding History

Signature Estate & Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Buy	6,802 +1,195	+21%	+$225K	0.02%	225
2026 Q1	$1.11M	Buy	5,607 +725	+15%	+$140K	0.02%	257
2025 Q4	$898K	Sell	4,882 -290	-6%	-$50.9K	0.02%	270
2025 Q3	$794K	Buy	5,172 +645	+14%	+$97.6K	0.02%	286
2025 Q2	$633K	Buy	4,527 +45	+1%	+$6.31K	0.01%	311
2025 Q1	$659K	Sell	4,482 -43	-1%	-$6.22K	0.02%	285
2024 Q4	$593K	Buy	4,525 +107	+2%	+$15K	0.01%	300
2024 Q3	$688K	Buy	4,418 +20	+0.5%	+$3.23K	0.02%	261
2024 Q2	$686K	Buy	+4,398	New	+$662K	0.02%	253

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Signature Estate & Investment Advisors's AZN Position: Q2 2026 in Review

Signature Estate & Investment Advisors increased its AstraZeneca (AZN) stake by 21% in Q2 2026, buying an estimated $225K and bringing the position to 6,802 shares worth $1.29M. The position accounts for 0.02% of the portfolio, ranked #225.

Signature Estate & Investment Advisors first reported a position in AZN in Q2 2024 and has held it in 9 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Signature Estate & Investment Advisors held 6,802 shares of AstraZeneca worth $1.29M as of Q2 2026.
Signature Estate & Investment Advisors bought 1,195 AstraZeneca shares in Q2 2026, an estimated $225K.
AstraZeneca made up 0.02% of Signature Estate & Investment Advisors's portfolio in Q2 2026, its #225 holding.
Signature Estate & Investment Advisors first reported a position in AstraZeneca in Q2 2024 and has held it in 9 quarters since.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Signature Estate & Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.